PatrickYungWenMD

Clinical Trials

• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Start of enrollment: 2001 Feb 27

  Completed

  Phase 1, Phase 2

• Imatinib Mesylate in Treating Patients With Recurrent Meningioma Start of enrollment: 2003 Feb 01

  Completed

  Phase 2

• Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Start of enrollment: 2004 Mar 01

  Completed

  Phase 2

• Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2001 Apr 01

  Completed

  Phase 2

• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2005 Apr 01

  Completed

  Phase 1, Phase 2

• Prolonged Daily Temozolomide for Low-Grade Glioma Start of enrollment: 2001 Sep 01

  Completed

  Phase 2

• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Sep 01

  Completed

  Phase 2

• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas Start of enrollment: 2005 Dec 16

  Active, not recruiting

  Phase 1

• Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Start of enrollment: 2007 May 25

  Completed

  Phase 1, Phase 2

• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01

  Completed

  Phase 2

• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma Start of enrollment: 2008 Jul 01

  Completed

  Phase 1

• Dose-Intense Temozolomide in Recurrent Glioblastoma Start of enrollment: 2008 May 01

  Completed

  Phase 2

• A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01

  Unknown status

  Phase 1, Phase 2

• Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor Start of enrollment: 2008 Jun 01

  Completed

  Phase 1

• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2009 Jul 10

  Completed

  Phase 1, Phase 2

• Monthly SOM230C for Recurrent or Progressive Meningioma Start of enrollment: 2009 Mar 01

  Completed

  Phase 2

• LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Start of enrollment: 2009 Mar 01

  Completed

  Phase 1, Phase 2

• PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Start of enrollment: 2010 Apr 01

  Completed

  Phase 2

• MK-2206 for Recurrent Malignant Glioma

  Withdrawn

  Phase 2

• Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01

  Completed

  Phase 1, Phase 2

• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Start of enrollment: 2011 Dec 01

  Terminated

  Phase 1

• Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 2

• BIBF 1120 for Recurrent High-Grade Gliomas Start of enrollment: 2012 May 01

  Completed

  Phase 2

• A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2011 Dec 30

  Completed

  Phase 1

• GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) Start of enrollment: 2011 Nov 01

  Terminated

  Phase 2

• Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2014 Feb 28

  Completed

  Phase 1

• ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01

  Completed

  Phase 2

• A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09

  Completed

  Phase 2

• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas Start of enrollment: 2014 Mar 03

  Terminated

  Phase 2

• Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30

  Terminated

  Phase 1

• A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Start of enrollment: 2016 Sep 21

  Completed

  Phase 1

• Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Start of enrollment: 2017 Oct 17

  Active, not recruiting

  Phase 2

• Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Sep 13

  Completed

  Phase 2

• Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07

  Terminated

  Phase 1

• A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Start of enrollment: 2018 Apr 02

  Recruiting

  Phase 1

• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30

  Recruiting

  Phase 2, Phase 3

• Abemaciclib + Pembrolizumab In Glioblastoma Start of enrollment: 2021 Dec 01

  Withdrawn

  Phase 2

• VB-111 in Surgically Accessible Recurrent/Progressive GBM Start of enrollment: 2020 Aug 01

  Active, not recruiting

  Phase 2

• Surgical Nivolumab And Ipilimumab For Recurrent GBM Start of enrollment: 2021 Feb 01

  Active, not recruiting

  Phase 1

• Surgical Pembro +/- Olaparib w TMZ for rGBM Start of enrollment: 2022 Oct 21

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact, Sponsor-Investigator

• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23

  Recruiting

  Phase 3

  Roles: Contact, Principal Investigator

• Join now to see all